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Alternative splicing of the Pkm gene product generates the PKM1 and PKM2 isoforms of pyruvate kinase (PK), and
PKM2 expression is closely linked to embryogenesis, tissue regeneration, and cancer. To interrogate the functional
requirement for PKM2 during development and tissue homeostasis, we generated germline PKM2-null mice
(Pkm2−/−). Unexpectedly, despite being the primary isoform expressed in most wild-type adult tissues, we found
that Pkm2−/−mice are viable and fertile. Thus, PKM2 is not required for embryonic or postnatal development. Loss
of PKM2 leads to compensatory expression of PKM1 in the tissues that normally express PKM2. Strikingly, PKM2
loss leads to spontaneous development of hepatocellular carcinoma (HCC) with high penetrance that is accompa-
nied by progressive changes in systemic metabolism characterized by altered systemic glucose homeostasis, in-
flammation, and hepatic steatosis. Therefore, in addition to its role in cancer metabolism, PKM2 plays a role in
controlling systemic metabolic homeostasis and inflammation, thereby preventing HCC by a non-cell-autonomous
mechanism.
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Changes inmetabolism accompany uncontrolled prolifer-
ation associated with tumor growth and progression
(Hanahan andWeinberg 2011). Cancer cells rewiremetab-
olism to meet the anabolic requirements of cell prolifera-
tion (Cairns et al. 2011). One of the main metabolic
aberrations associated with cancer is a fundamental chan-
ge in glucose metabolism. In particular, isoform selection
of the glycolytic enzyme pyruvate kinase (PK) impacts the
fate of glucose in cells and has been implicated in themet-
abolic phenotype of cancer cells. Two separate genes en-
code PK enzymes in mammals, and each gene gives rise
to two isoforms (Takenaka et al. 1996). The Pklr gene en-
codes PKL, which is expressed mainly in hepatocytes and
some cell types in the kidney, intestine, and pancreas, and
PKR, which is expressed in erythrocytes. The Pkm gene
encodes PKM1 and PKM2 through mutually exclusive
alternative splicing of exons 9 and 10 of this gene (Nogu-
chi et al. 1987).
While PKM1 is often referred to as the adult-specific
isoform, PKM2 has been shown to be expressed during
embryogenesis, tissue regeneration, and tumor develop-
ment (Mazurek 2011). However, the expression pattern
of the two different PKM isoforms across adult tissues
and cell types is incomplete. While some reports suggest
that PKM2 expression is unique to cancer cells and other
proliferating cell types (Lu 2012; Yang et al. 2012c; Wong
et al. 2014), many other studies contradict this generaliza-
tion and report PKM2 expression in select normal tissues
(Clower et al. 2010; David et al. 2010; Mazurek 2011). Per-
haps as a consequence of the uncertainty surrounding its
expression in adult cell types and the lack of a definitive
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characterization in major adult tissues, relatively few
studies have focused on the role of PKM2 in normal prolif-
erating cells (e.g., embryo and intestine) or in the normal
quiescent tissues that express PKM2.
Although PKM1 and PKM2 differ by only a single exon,
their enzymatic activity is regulated very differently.
Whereas PKM1 is a constitutively active enzyme, PKM2
enzymatic activity is regulated by a variety of allosteric ef-
fectors and post-translational modifications (Christofk
et al. 2008b; Lv et al. 2011; Mazurek 2011; Chaneton et al.
2012). Due to its near universal expression in cancer,
PKM2 has been extensively studied in this context. In par-
ticular, the different consequences of PKM1 expression
versusPKM2expressionsuggest that theability to regulate
PKenzymaticactivitymakesPKM2morepermissiveofthe
metabolic state required of proliferation. Replacement of
PKM2withPKM1inculturedcells influenceshowglucose
is metabolized, limiting flux through anabolic pathways
and thereby preventing xenograft tumor formation (Chris-
tofk et al. 2008a; Lunt et al. 2015). Increased PK activity
through small molecule activation of PKM2 also impairs
tumor growth in mice (Anastasiou et al. 2012). Further-
more, potential nonglycolytic functions of PKM2 have
been proposed (Luo et al. 2011; Yang et al. 2011, 2012a,b,
c;Gaoetal. 2012;Lu2012;Kelleret al. 2014)butarecontro-
versial (Hosios et al. 2015). Despite numerous studies of
PKM2 in cultured tumor cells, whether PKM2 is required
for cell proliferation in vivo remains a topic of debate.
Thisquestion is relevant to thepotential ofPKM2asa ther-
apeutic target for cancer and other human diseases.
In this study, we provide conclusive evidence that
PKM2 expression iswidespread in bothmouse and human
adult tissues, with distinct and cell type-specific ex-
pression patterns of PKM isoforms that suggest nonredun-
dant functional requirements in different cell types.
Nonetheless, complete loss of PKM2 using a genetically
engineered mouse model is compatible with normal
development. In-depth analysis of aging PKM2-null
(Pkm2−/−) animals revealed an unexpected role for PKM2
in controlling systemic glucose homeostasis. Moreover,
Pkm2−/−mice develop late-onset spontaneous hepatocel-
lular carcinomas (HCCs) with high frequency, recapitulat-
ing the correlation between metabolic disease and HCCs
observed in humans. Further molecular analysis revealed
some of the gene expression and metabolite changes that
precede liver tumorigenesis, establishing aging Pkm2−/−
mice as a model for how progressive systemic metabolic
aberrations and hepatocyte non-cell-autonomous changes
can lead to the development of HCCs.
Results
Germline loss of PKM2 leads to PKM1 expression
and is compatible with normal mouse development
To investigate the role of PKM2 in adult mice, we crossed
mice with a Pkm2 conditional allele (Israelsen et al. 2013)
to mice carrying a Cre transgene under the EIIA promoter
(Lakso et al. 1996) in order to generate mice heterozygous
for a germline loss-of-function Pkm2 (Pkm2−) allele
(Supplemental Fig. S1A). Importantly, this Pkm2− allele
does not prevent expression of PKM1 (Israelsen et al.
2013). Pkm2 heterozygotes (Pkm2+/−) were intercrossed
to generate homozygous (Pkm2−/−) mice (Supplemental
Fig. S1B). Despite the fact that PKM2 is the primary iso-
form expressed in the embryo (Mazurek 2011), we found
that Pkm2−/− mice were viable, grossly normal, and
born at the expected 1:2:1 Mendelian ratio (Table 1).
To characterize expression of PKM1 and PKM2 in wild-
type and Pkm2−/−mice at the cell and tissue level, we per-
formed immunohistochemistry (IHC) staining of embry-
onic day 14.5 (E14.5) mouse embryos using antibodies
specific to either PKM1 or PKM2. With the exception of
cells in the fetal liver, all cells in wild-type embryos ex-
pressed PKM2 (Fig. 1A). Pkm2−/− embryos, on the other
hand, expressed PKM1, suggesting that PKM1 expression
in this context is compatible with embryonic develop-
ment. While PKM2 is the predominant isoform in most
wild-type adult tissues, PKM1 was the predominant iso-
form in all of the adult Pkm2−/− tissues examined (Fig.
1B,C). IHC analysis of adult wild-type tissues identified
specific PKM2-expressing cell types within select tissues,
including kidney tubular cells, intestinal epithelial cells,
pancreatic islet cells, and lung epithelial cells (Fig. 1C).
Analysis of the same tissues isolated from Pkm2−/−mice
revealed PKM1 expression in these cell types. Other
PKM2-expressingcell types inwild-typemiceincludesper-
matogonia, the cortex cells of the adrenal glands, and the
choroidplexuscellsof thebrain (SupplementalFig.S1C,D).
To validate the PK isoform expression patterns noted in
adult wild-type mouse tissues by an independent method
and determine whether human tissues show a similar ex-
pression pattern, we analyzed two publicly available data
sets with tissue-specific RNA-sequencing (RNA-seq) data
present for bothmouse and human tissues (The ENCODE
Project Consortium 2012; Illumina Human Body Map
2.0). Low inclusion of the PKM1-specific exon 9 was ob-
served in most tissues (Fig. 2A,B), confirming that PKM2
is the predominant isoform in many adult mouse and hu-
man tissues. The human RNA-seq data were also consis-
tent with expression analysis of human tissue by IHC for
PKM1 and PKM2 (Supplemental Fig. S2A).
In agreementwith the protein analysis of PK isoform ex-
pression in wild-type and Pkm2−/− mice, quantitative
RT–PCR (qRT–PCR) analysis of the same tissue revealed
a switch from PKM2 to PKM1 in Pkm2−/− tissues (Fig.
2C). Similarly, the transcript levels for PKM1 were dra-
matically increased in Pkm2−/− tissues relative to wild-
type tissues. This quantitative approach also revealed
that the levels of total Pkm transcripts were reduced in
null tissues compared with wild type (Fig. 2C). Lower
Table 1. Litters from Pkm2+/− crosses show Mendelian ratios
Pkm2+/+ Pkm2+/− Pkm2−/−
Number
of litters Ratio
Actual 44 86 29 34 1:2:0.7 (n.s.)
Expected 39.5 79.5 39.5 — 1:2:1
(n.s.) P > 0.05, χ2 analysis.
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Pkm transcript levels in Pkm2−/−mouse tissues might be
explained in part by the observation that a percentage of
the transcripts from the Pkm2− locus results in exon skip-
ping that generates PKMskip (Supplemental Fig. S2B), an
mRNA species that is degraded by nonsense-mediated de-
cay (Israelsen et al. 2013). Interestingly, the decrease in to-
tal levels of Pkm transcripts was accompanied by a
reduction in the maximum rate of reaction (Vmax) for PK
enzyme activity in Pkm2−/− tissue lysates from the kid-
ney, lung, and colon (Fig. 2D; Supplemental Fig. S2C).
The decrease in PK enzymatic activity appears to be spe-
cific to Pkm2−/− tissue that normally expresses PKM2,
as there was no change in the PK enzymatic activity of ly-
sates from Pkm2−/− skeletal muscle or liver tissue com-
pared with wild type (tissues that express PKM1 and
PKL, respectively). Collectively, these data demonstrate
that PKM2 expression is not restricted to or necessary
for the viability of proliferative cells or tissues that have
a high rate of cell turnover (Table 2).
PKM2-null mice develop late-onset spontaneous HCC
Since Pkm2−/− mice did not display any overt develop-
mental defects, we examined the consequences of PKM2
loss in adultmice. Pathological analysis of the lungs, liver,
kidneys, intestines, heart, skeletalmuscle, spleen, pancre-
as, brain, and reproductive organs from young homozy-
gous mutant mice did not reveal any morphological
differences (data not shown). Strikingly, however, aged
PKM2-deficient mice displayed a dramatic incidence of
liver tumors. Macroscopic inspection of livers from
Pkm2−/−mice between 55 and 94 wk of age revealed that
many aged Pkm2−/−mice developed multiple macroscop-
ic liver tumors that occupy between 30% and 80% of the
liver (Fig. 3A). Histological analysis indicated that the
tumors were low- tomid-grade HCCs with a high prolifer-
ative index, as revealed by incorporation of 5-bromodeox-
yuridine (BrdU) (Fig. 3B,C). Moreover, we identified
various histological patterns showing that there was het-
erogeneity across tumor lesions even within the same
liver (Fig. 3B). Interestingly, therewasaclear genderdispar-
ity with regard to the incidence of HCC. Whereas 65% of
aged Pkm2−/− male mice developed HCC, only 22% of
the age-matched female littermates exhibited this pheno-
type (five out of 23 mice) (Supplemental Fig. S3A). Age-
matched male and female mice heterozygous for the
Pkm2-null allele also developed tumors, albeit with a low-
er incidence (33% and 14%, respectively). By comparison,
small adenomas were occasionally observed in aged wild-
type mice, but none progressed to HCC (Fig. 3D).
The observation that Pkm2−/− mice developed sponta-
neous HCCs was unexpected for multiple reasons. Al-
though a subset of HCCs is thought to arise from
hepatic progenitor cells (HPCs),mostHCCs arise fromdif-
ferentiated hepatocytes (Tschaharganeh et al. 2014; Mar-
quardt et al. 2015). The PK isoform expression of HPCs
is unknown; however, differentiated hepatocytes do not
express PKM2 (Supplemental Fig. S3B–D) but instead
express the liver-specific PKL isoform (Mazurek 2011).
Furthermore, previous reports have suggested that forma-
tion of HCCs involves a change in PK isoform expression
from PKL to PKM2 (Hacker et al. 1998; Wong et al. 2014).
Therefore, we hypothesized that HCCs in Pkm2−/− mice
express PKM1.
Figure 1. Germline loss of PKM2 leads to expression
of PKM1. (A) Representative images of IHC for PKM1
and PKM2 in wild-type (M2+/+) and Pkm2-deficient
(M2−/−) mouse embryos harvested at E14.5. Bars,
500 μm. (B) Western blot analysis for PKM2 protein
on tissue lysates from M2+/+, M2+/−, or M2−/− mice.
β-Tubulin was used as a loading control. (C ) Repre-
sentative images of IHC for PKM1 and PKM2 in
M2+/+ (left set of panels) andM2−/− (right set of panels)
tissues. Corresponding hematoxylin and eosin (H&E)
images are shown. Bars, 20 μm.
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To investigate the PK expression pattern of tumors and
livers from Pkm2−/− and wild-type mice and distinguish
tumor cells and differentiated hepatocytes from stromal
cells, we performed dual-color IHC for amarker of hepato-
cyte differentiation, HNF4α, with PKM1 or PKM2 anti-
bodies (Fig. 3E; Supplemental Fig. S3C,E). We found that
while Pkm2−/− tumors contained cells that expressed
PKM1, the majority of these cells were not tumor cells
(Fig. 3E). In fact, colocalization of HNF4α and PKM1 was
only occasionally observed in tumors from Pkm2−/−
mice. The majority of PKM1-expressing cells present in
both tumors and non-tumor-bearing livers from Pkm2−/−
mice were stromal cells.
Our observations inPkm2−/−HCCraised the possibility
that PKM2 might not be the predominant isoform in the
benign liver lesions found inwild-typemice. In fact, theex-
pressionpattern forPKM2inbothwild-type liversand liver
adenomas was similar to the PKM1 expression pattern
found in Pkm2−/− livers and HCC (Supplemental Fig.
S3F). To determine whether these observations were rele-
vant to the human disease, we analyzed RNA-seq data
Figure 2. PKM2 is the predominant iso-
form in mouse and human tissues, and
germline loss of PKM2 leads to decreased
levels of total PK. RNA-seq read coverage
across Pkm exons 8–11 of adult mouse tis-
sue (A) andPKM exons 8–11 of adult human
tissue (B). MISO (Katz et al. 2010) percent-
age spliced-in (Ψ) values for inclusion of
exon 9 (corresponding to the Pkm1 isoform)
are shown at the right for each tissue. The
regions that correspond to each exon and
the direction of transcription are indicated
below. (C ) Expression of PKM1, PKM2,
and total Pkm mRNA in tissue isolated
from M2+/+, M2+/−, or M2−/− mice was as-
sessed by quantitative RT–PCR (qRT–
PCR). (D) PK enzymatic activity assays in
kidney, lung, colon, skeletal muscle (gas-
trocnemius), or liver tissue lysates isolated
from M2+/+, M2+/−, or M2−/− mice. For C
and D, P-values using unpaired t-test are
shown. (∗) P < 0.05; (∗∗) P < 0.01. n = 3 mice.
Table 2. Summary of PKM1 and PKM2 expression patterns
across adult mouse tissues
Tissue/cell type PKM1 PKM2
Heart +++ —
Skeletal muscle +++ —
Smooth muscle ++ —
Brain +++ +
Kidney — +++
Pancreatic islet cells + +++
Intestine + +++
White fat — +++
Lung — +++
Lymphocytes — +++
Thymus — +++
Spleen — +++
Ovaries + +++
Testis ++ ++
Adrenal gland ++ +++
(+, ++, and +++) Level of expression from low to high; (—) no
expression.
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from human HCCs (The Cancer Genome Atlas [TCGA];
https://tcga-data.nci.nih.gov/tcga), and performed IHC for
PKM2 on primary human tumor sections (Supplemental
Fig. S3G,H). Both analyses revealed heterogeneous PKM2
expression across human HCCs, with some tumors show-
ing very high expression of PKM2 and others showing very
low levels of PKM2.These data argue that increasedPKM2
expression is not a universal feature of hepatic neoplasia in
mice or humans. Furthermore, Pkm2−/− mice develop
spontaneousHCC inwhich neither PKM isoform is signif-
icantly expressed, arguing that PKM2 is not required for
the growth of benign or malignant liver tumors.
HCCs in PKM2-null mice show diverse oncogenic
driver events
The fact that PKM2 is not expressed in benign liver lesions
from wild-type mice and that PKM1 is not the predomi-
nant isoform expressed inHCC from Pkm2−/−mice raised
the possibility that HCC in Pkm2−/− mice was arising
from a stochastic process influenced by non-cell-autono-
mous factors. Therefore, we asked whether HCCs in
Pkm2−/− mice shared common molecular changes. Re-
cent exome sequencing of human HCCs has identified
11 recurrently altered pathways, including WNT/β-cate-
nin, Tp53/cell cycle, oxidative stress, mitogen-activated
protein kinase (MAPK), and interleukin (IL)-6/JAK–
STAT (Schulze et al. 2015). To determinewhether tumors
from Pkm2−/− mice exhibited alterations in these path-
ways, we performed targeted qRT–PCR and IHC analysis
(Fig. 3F,G). IHCof β-catenin in tumors fromPkm2−/−mice
revealed cells with nuclear localization of β-catenin in
more than half of the tumors analyzed. Next, we assessed
MAPK signaling by IHC for phosphorylated p42/p44
MAPK (pERK) and detected pathway activation in 13
out of 29 tumors. We also found one tumor that showed
strong nuclear staining for p53, potentially indicative of
a p53mutation (Olive et al. 2004). Finally, we interrogated
Figure 3. Aged PKM2-null mice develop
spontaneous HCC with high penetrance.
(A) Representative macroscopic images of
livers harvested from aged wild-type or
M2−/− mice. The table indicates the fre-
quency of HCC in male mice, as identified
at necropsy. (B) Representative H&E imag-
es of liver tumors from aged M2−/− mice.
Bars: left images, 100 μm; right images,
20 μm. (C ) Quantification of BrdU-positive
cells in the livers and HCC sections of
agedM2+/+ orM2−/−mice. A representative
10× image of IHC for BrdU in anM2−/− tu-
mor is shown. Bar, 100 μm. Means and P-
value using unpaired t-test are indicated.
(∗∗∗∗) P < 0.0001. (D) Summary of hepatic
adenoma and HCC incidence in M2+/+ and
M2−/− male mice. (E) Dual-color IHC for
PKM1 (brown) and total HNF4α (purple) in
M2−/− HCC. Bars: left, 100 μm; right,
20 μm. (F ) Representative images of IHC
for β-catenin, pERK, p53, or NQO1 on
M2−/− HCC. Bar, 20 μm. (Bottom right) Ex-
pression of Nqo1 mRNA as determined by
qRT–PCR in wild-type livers,M2−/− livers,
or M2−/− HCC. Mean ± SEM and P-values
using unpaired t-test are shown. (∗) P <
0.05. (G) Quantification of IHC results for
different markers of active oncogenic
pathways.
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changes in the oxidative stress pathway in Pkm2−/− tu-
mors through qRT–PCR and IHC analysis of Nqo1, a ca-
nonical Nrf2 target gene. Out of seven tumors analyzed,
five had increased Nqo1 levels compared with healthy
wild-type and Pkm2−/− livers. Some tumors also showed
up-regulation ofHmox1 andGclc, two additionalNrf2 tar-
get genes (Supplemental Fig. S3I). Consistent with the in-
crease in oxidative stress that we observed in Pkm2−/−
tumors, livers and tumors from Pkm2−/− mice displayed
evidence of DNA damage, as indicated by increased levels
of γ-H2AX protein as compared with wild-type livers
(Supplemental Fig. S3J). Taken together, these results sug-
gest that loss of PKM2 predisposes livers to spontaneous
tumor development through a stochastic process that
causes a variety of potential genetic driver events, some
of which target the same pathways that are often altered
in the human disease.
Germline loss of PKM2 induces discrete metabolite and
gene expression changes in the liver that precede HCC
Overt HCC development did not become apparent in
Pkm2−/−malemice until ∼60–88 wk of age. Nonetheless,
we hypothesized that changes in liver metabolites, gene
expression, or both might precede tumor formation in
these mice. Thus, we probed the metabolite and gene ex-
pression profiles of livers from Pkm2−/−mice at 35 wk of
age, a time point prior to any overt histological evidence of
tumors (Fig. 4A). Because HCC development is favored in
Pkm2−/− male mice, we focused our analysis on these
animals.
Global metabolite profiles of livers from 35-wk-old
male mice with and without germline loss of PKM2 re-
vealed a 16-metabolite signature that distinguished
Pkm2−/− from wild-type livers (Fig. 4B; Supplemental
Tables S1, S2). Moreover, both unsupervised clustering
and principal component analysis (PCA) showed that
Pkm2−/− livers exhibited consistent metabolite changes
(Supplemental Fig. S4A,B). Although the metabolite
changes found in Pkm2−/− livers did not reveal an obvious
pattern of liver dysfunction at this time point, we did
observe metabolite changes consistent with early stages
of disease. Of note, phosphocholine and fructose-6-
phosphate, twometabolites whose increase has been asso-
ciated with proliferation and malignant transformation
(Tong et al. 2009; Glunde et al. 2011; Jain et al. 2012; Patra
and Hay 2014), were increased in PKM2-null livers
(Fig. 4B).
RNA-seq analysis of livers from35-wk-oldPkm2−/− and
control mice revealed significant changes in gene ex-
pression (Fig. 4C; Supplemental Table S3). Unsupervised
clustering showed that the three null samples cluster
closely together, suggesting that germline loss of PKM2
elicits consistent gene expression changes in the liver
(Supplemental Fig. S4C). We used gene set enrichment
analysis (GSEA) to identify statistically enriched gene
sets within gene expression changes in the livers from
PKM2-null mice (Subramanian et al. 2005). Surprisingly,
despite a lack of overt morphological changes in
Pkm2−/− livers at this time, we found enriched gene sets
from a diverse set of HCC models (Supplemental Fig.
S4D; Supplemental Table S4). Significant gene set
Figure 4. Metabolite and RNA-seq pro-
files of prediseased livers reveal early
changes in PKM2-null mice. (A) Represen-
tative H&E images of livers from M2+/+
and M2−/− male mice at the indicated
ages. Bars, 20 μm. Heat maps of differen-
tially expressed metabolites (B) and differ-
entially expressed genes (C ) (RNA-seq;
false discovery rate < 0.05; fold change >
1.5) identified in livers of 35-wk-old M2+/+
or M2−/− mice. (D) The top up-regulated
(top) and down-regulated (bottom) canoni-
cal pathways based on differentially ex-
pressed genes identified in C, analyzed by
Ingenuity Pathway Analysis (IPA).
PKM2 loss promotes metabolic distress and HCC
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enrichment resulted only from down-regulated genes in
our data set. Furthermore, Ingenuity Pathway Analysis
(IPA; Qiagen, http://www.qiagen.com/ingenuity) sug-
gested that the enriched pathways fell into two main
categories: immune responses and metabolic regulation
(Fig. 4D).
In the category of metabolic regulation, we were partic-
ularly interested in the observation that RNA-seq differ-
ential expression analysis showed up-regulation of the
sterol regulatory element-binding transcription factor 1
(Srebf1), which regulates genes involved in lipid bio-
synthesis. Up-regulation of Srebf1 in hepatocytes has
been implicated in both fatty liver and hepatocarcinogen-
esis (Horie et al. 2004; Knebel et al. 2012). Interestingly,
we also observed down-regulation of the UDP-glucose
transporter Slc35d2, a finding consistent with reduced
levels of the metabolite UDP-glucose in Pkm2−/− livers
(Fig. 4B).
In the category of immune responses, we noted up-reg-
ulation of Il18 and leukocyte-derived chemotaxin 2 (Lect).
We also detected increased expression of genes associated
with proliferation and oncogenesis, including Mapk15
and Erbb4. The expression patterns for Srebf1, Ucp2,
Ide1, Erbb4, and another target, Nt5e, were validated by
qRT–PCR in the same experimental samples used for
the RNA-seq analysis as well as in four additional inde-
pendent liver samples (Supplemental Fig. S4E).
PKM2-null mice display increased high-fat diet
(HFD)-induced metabolic distress and inflammation
and increased hepatocyte proliferation
IPA analysis of the gene expression changes that we ob-
served in the livers of Pkm2−/− mice suggested that both
inflammation and metabolic pathways were altered prior
to tumor development. Moreover, because we observed a
reduction in both total Pkm expression and maximal PK
enzymatic activity in Pkm2−/− tissues peripheral to the
liver and because Pkm is important for glucose metabo-
lism, we hypothesized that glucose homeostasis and met-
abolic function might be impaired in Pkm2 mutant
animals. To determine whether young Pkm2−/− mice
are more prone to develop metabolic disease if placed un-
der metabolic stress, groups of 8- to 12-wk-old wild-type
and Pkm2−/− male mice were fed either a low-fat diet
(LFD; 10% calories from fat) or a HFD (60% calories
from fat) for 10 wk.
Pkm2−/− mice fed a HFD displayed increased weight
gain compared with wild-type mice on the same diet,
which could not be explained by differences in food intake
(Fig. 5A; Supplemental Fig. S5A).Mice exposed to the LFD
did not display any significant difference in weight gain
(Supplemental Fig. S5B). Furthermore, after 6 wk on a
HFD, Pkm2−/− mice had increased fasting blood glucose
levels that were accompanied by a trend toward an
Figure 5. PKM2-null mice are sensitive to HFD-in-
ducedmetabolic distress. (A) Weeklyweightmeasure-
ments of 8- to 12-wk-oldM2+/+ andM2−/− male mice
fed a HFD. Blood glucose (B) and serum insulin (C )
were measured in fasted (16 h) M2+/+ or M2−/− mice
fed a HFD or LFD for 6 wk. (B) The fasting glucose lev-
els of mice before being placed on either diet are
shown at the left. (D) Levels of ALT were measured
in serum of M2+/+ or M2−/− mice after 6 wk on a
HFD. (E) Ratio of liver weight to body weight of
mice fed a HFD at the end of the 10-wk regimen. (F )
Representative H&E images of livers from M2+/+ and
M2−/− male mice after a 10-wk HFD regimen. Bars,
20 μm. (G) Triglyceride (TG) concentrations were
measured in the livers of fedM2+/+ orM2−/−mice after
10 wk on a HFD. (H) Quantification of Iba1+ macro-
phages in livers from M2+/+ or M2−/− mice fed a
HFD for 10 wk. Representative images of the IHC
for Iba1 are shown. Bars, 20 μm. (I ) Quantification of
BrdU-positive cells in livers from M2+/+ or M2−/−
mice fed a HFD for 10 wk. Means ± SEM and P-values
using unpaired t-test are shown. (∗) P < 0.05; (∗∗) P <
0.01; (∗∗∗) P < 0.001.
Dayton et al.
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increase in fasting insulin (Fig. 5B,C). Pkm2−/− mice also
exhibited signs of liver damage after 6 wk of exposure to
a HFD, as evidenced by increased serum alanine amino-
transferase (ALT) compared with wild-type littermate
controls (Fig. 5D).
At the end of the 10-wk regimen, livers from Pkm2−/−
mice fed a HFD were twofold larger relative to body
weight than those of wild-type controls (Fig. 5E). Whereas
livers from wild-type mice on a HFD only had moderate
steatosis, Pkm2−/−mice on the same diet exhibited severe
hepatic steatosis (Fig. 5F) and increased liver triglyceride
content (Fig. 5G). Livers from both wild-type and
Pkm2−/− mice fed a LFD displayed only mild steatosis,
and the liver weight to body weight ratio was similar in
each cohort (Supplemental Fig. S5C,D). In addition, the
liver area that stained positive for a common macrophage
marker, IBA1, was higher in livers from Pkm2−/−mice fed
a HFD as compared with wild-type mice on the same diet
(Fig. 5H), indicating more macrophage infiltration in the
liver in response to the HFD.
Finally, after 10 wk of exposure to a HFD, the livers of
Pkm2−/− mice showed higher BrdU incorporation com-
pared with livers of Pkm2+/+ mice on the same diet (Fig.
5I; Supplemental Fig. S5E). These data demonstrate that
PKM2 deficiency exacerbates HFD-induced metabolic
distress and liver inflammation in adult male mice. Fur-
thermore, the observation of increased hepatocyte prolif-
eration in the livers of Pkm2−/− mice exposed to a HFD
suggests that these two conditions—metabolic distress
and inflammation—create a liver microenvironment
that is more prone to tumor development.
PKM2-null mice display increased age-induced
metabolic distress and inflammation and increased
hepatocyte proliferation
The fact that Pkm2−/−male mice were more prone to the
metabolic distress induced by a HFD argues that loss of
PKM2 and the consequent aberrant expression of PKM1
in Pkm2−/− mice lead to increased susceptibility to
metabolic stress. Furthermore, becauseHCC is associated
with systemic metabolic disease, including type 2 diabe-
tes, metabolic syndrome, and NAFLD (Leung et al.
2015), and because changes in PK isoform expression
can impact glucose fate (Lunt et al. 2015), we asked
whether Pkm2−/−mice might likewise be more suscepti-
ble to age-induced whole-body metabolic changes. We
measured fasting blood glucose and insulin levels in
young and old Pkm2−/− mice or wild-type littermates.
Glucose and insulin levels were not altered in young
Pkm2−/−mice, andwe found that these animals had a nor-
mal glucose tolerance test (GTT) (Fig. 6A,B; Supplemental
Fig. S6A). Older Pkm2−/− male mice (≥85 wk), however,
had increased fasting blood glucose and insulin levels
as compared with wild-type littermates (Fig. 6A,B). A sim-
ilar trend was observed in female mice, but only the dif-
ference in fasting glucose was statistically significant
(Supplemental Fig. S6B,C).
Consistent with metabolic distress in Pkm2−/− male
mice, the majority of these mice also developed hepatic
steatosis consisting of both macrovesicular and microve-
sicular patterns of lipid accumulation (Fig. 6C). Livers
from Pkm2−/− and wild-type mice were scored for the de-
gree of steatosis as negative, mild, intermediate, and
severe.All of themutantmice inour analysis showedsigns
of steatosis, with∼50%of themice displaying severe stea-
tosis (Fig. 6D). Aged Pkm2−/− males also showed a subtle
but significant increase in weight (Supplemental Fig.
S6D). Increased concentrations of ALT in the serum of
aged Pkm2−/− males suggested increased liver damage in
older mice (Fig. 6E). Taken together, these data show
that HCC in Pkm2−/− mice is accompanied by features
of systemic metabolic disease, including hyperglycemia,
hyperinsulinemia, and hepatic steatosis.
Consistent with our analysis of Pkm2−/−mice exposed
to a HFD, we found that livers from aged Pkm2−/− mice
(59-wk; no macroscopic HCC) showed increased macro-
phage infiltration, as indicated by IHC for IBA1 (Fig. 6F).
Human patients with systemic metabolic disease also ex-
hibit increased systemic inflammation (Rahman et al.
2013), and increased circulating Interleukin-6 (IL-6) is as-
sociated with this type of obesity-induced inflammation
(Mauer et al. 2015). Therefore, we characterized the circu-
lating cytokine profile of young and old Pkm2−/− male
mice together with age- and sex-matched wild-type litter-
mate controls. No differences in cytokine levels were ob-
served in the serum of 12-wk-old Pkm2−/− mice;
however, 85-wk-old mutant mice showed a consistent
increase in serum IL-6 (Fig. 6G). Furthermore, qPCR
analysis of white adipose tissue from the same mice
revealed increased levels of Tnfα mRNA in Pkm2−/− tis-
sue compared with wild-type (Supplemental Fig. S6E).
The levels of CD45 and F4/80 mRNA were also in-
creased in tissue from mutant animals, suggesting in-
creased immune cell infiltration in adipose tissue and
consistent with our observations of increased systemic
inflammation.
These results led us to revisit Il18, a chemokine gene
identified in our RNA-seq analysis and whose transcript
levels were increased in the livers of Pkm2−/− mice com-
pared with age- and sex-matched wild-type mice (Fig. 4C;
Supplemental Table S3). We confirmed these results in
livers from 35-wk-old Pkm2−/− and wild-type mice by
qRT–PCR analysis and also found that the up-regulation
of Il18 mRNA was more pronounced in the livers of 85-
wk-old Pkm2−/− mice than in livers of younger mice
and wild-type controls (Fig. 6H). The increase in Il18
mRNA in Pkm2−/− livers relative to wild-type livers
was accompanied by an increase in IL18 protein levels
and, importantly, the levels of the cleaved/active form
of the cytokine (Fig. 6I). IL18 has been implicated in
both chronic hepatic inflammation and the development
of diethylnitrosamine (DEN)-induced HCC in mice
(Li et al. 2015).
Chronic inflammation in the setting of obesity andmet-
abolic disease is thought to cause liver injury with cycles
of compensatory proliferation that eventually lead to
HCC development (Farazi and DePinho 2006). Further-
more, IL18 has been shown to promote hepatocyte prolif-
eration following partial hepatectomy in rats (Zhang et al.
PKM2 loss promotes metabolic distress and HCC
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2014). Therefore, we asked whether livers from older
Pkm2−/− mice show increased rates of proliferation. To
test this hypothesis, we analyzed BrdU incorporation in
the livers of 54-wk-old Pkm2−/− male mice, a time point
with low penetrance of HCC. Compared with wild-type
livers, Pkm2−/− livers showed an increase in the number
of BrdU+ cells (Fig. 6J). Collectively, these findings suggest
that HCC in Pkm2−/−mice is accompanied by metabolic
imbalance and hepatic inflammation, both of which
appear to be progressive processes that become more pro-
nounced with age, are associated with increased hepato-
cyte proliferation, and culminate in the development of
HCC.
Discussion
The observations that PKM2 is not required for embryonic
and postnatal development and that Pkm2−/− mice
develop spontaneous HCC challenge some existing mod-
els of PKM2 function and suggest that this isoform is dis-
pensable for both normal cell and HCC proliferation.
Importantly, our results also indicate that PKM2 and
PKM isoform selection play a previously unappreciated
role in maintaining systemic energy homeostasis and
thereby in preventing spontaneous HCC.
Role of PKM2 in embryonic and postnatal development
PKM2 is universally expressed in tumors and can play a
role in regulating glycolysis and therefore the metabolic
phenotype of cancer cells (Christofk et al. 2008a). A num-
ber of other studies have suggested that PKM2 expression
in cancer cells is driven by its unique protein kinase or nu-
clear functions (Lv et al. 2011; Gao et al. 2012; Yang et al.
2011, 2012b,c). Our observation that PKM2 is not required
for normal embryonic or postnatal development indicates
that both the canonicalmetabolic and putative noncanon-
ical nuclear functions of PKM2 are not required for nor-
mal proliferation or organismic viability.
Importantly, loss of PKM2 results in aberrant expres-
sion of PKM1, arguing that, in the contexts of embryonic
and postnatal development, PKM1 can compensate for
the lack of PKM2. This is surprising for several reasons.
First, the distinct tissue and cell type-specific expression
patterns of PKM1 and PKM2 in wild-type tissue suggest
nonredundant functions for each isoform. Second, the
Figure 6. HCC in PKM2-null mice is ac-
companied by metabolic distress and pre-
ceded by hepatic inflammation and
increased hepatocyte proliferation. Blood
glucose (A) and serum insulin (B) weremea-
sured in fasted (16 h)M2+/+ orM2−/−mice of
the indicated ages. (C ) Representative H&E
images of livers from 54- to 62-wk-old
M2+/+ and M2−/− male mice reveal hepatic
steatosis inM2−/−mice. Bars, 20 μm. (D) De-
gree of steatosis was graded as none, mild,
intermediate, or severe according to the pro-
portion of total liver displaying a steatosis
phenotype. (E) Levels ofALTweremeasured
in serum of young (24 wk) or old (85 wks)
M2+/+ or M2−/− mice. (F ) Quantification of
macrophages (Iba1+ area) in livers from
M2+/+ or M2−/− mice fed a HFD for 10 wk.
Representative images of Iba1 IHC are
shown. Bars, 20 μm. (G) Levels of IL-6 in
the serum of young (12 wk) and aged (85
wk)M2+/+ andM2−/−micewere determined
by multiplex array. (H) Expression of Il18
mRNA in the livers of young (35 wk) or
aged (85 wk) M2+/+ and M2−/− male mice
as determined by qRT–PCR. (I ) Western
blot analysis for IL-18 on whole liver tissue
lysates from young (top) and aged (bottom)
M2+/+ or M2−/− mice. Hsp90 was used as a
loading control. (J) Quantification of BrdU-
positive cells in liver sections of 40- to
56-wk-old M2+/+ or M2−/− mice. Means ±
SEM and P-values using unpaired t-test are
shown. (∗) P < 0.05; (∗∗) P < 0.01; (∗∗∗) P <
0.001; (n.s.) P > 0.05.
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enzymatic activities of PKM1 and PKM2 are regulated by
distinct mechanisms. While PKM1 is constitutively ac-
tive, PKM2can be inhibited by a variety of cellular signals,
many of which are known to promote cell and tissue
growth (Mazurek et al. 2005; Christofk et al. 2008b; Hito-
sugi et al. 2009; Vander Heiden et al. 2010; Lv et al. 2011).
The lower expression of total Pkm observed in PKM2-ex-
pressing tissues from Pkm2−/−mice argues that lower PK
activity associated with PKM2 regulation is important for
tissues that normally express PKM2. Whether changes in
PKM1 expression levels allow tissues that would other-
wise use allostericmechanisms to regulate PKM2 activity
to access different levels of enzyme activity remains an
open question.
Previous studies of primary cells in culture suggest that
the constitutive enzymatic activity associated with
PKM1 expression can be incompatible with rapid prolifer-
ation (Lunt et al. 2015). Acute deletion of PKM2 in un-
transformed cultured cells leads to proliferative arrest
(Lunt et al. 2015), and activation of PKM2 enzymatic ac-
tivity by small-molecule activators, which renders the en-
zyme more similar to PKM1, impedes xenograft tumor
formation in mice (Anastasiou et al. 2012). Furthermore,
in a mouse model of leukemia, uniform expression of
PKM1 limited tumor progression (Wang et al. 2014). In a
breast cancer model, on the other hand, heterogeneous
PKM1 expression across tumors cell populations allowed
the tumor cells with lower PKM1 expression to proliferate
and thus did not impede tumor progression (Israelsen et al.
2013). Although similar to what was observed in HCC in
PKM2-null mice, many breast cancer cells were found to
express neither PKM1 nor PKM2 at appreciable levels
(Israelsen et al. 2013).
In contrast to these findings in cancer, we saw uniform
expression of PKM1 in Pkm2−/− embryos and nonetheless
found that embryonic development, a process that re-
quires rapid proliferation, was unperturbed. The ability
of Pkm2−/− cells to proliferate in the absence of PKM2
and despite the expression of PKM1 raises the possibility
that the role of PK regulation in normal proliferation, as
seen during embryonic development or normal tissue ho-
meostasis, may differ from that in cancer. Of note, the
consequences of increased constitutive PK enzymatic ac-
tivity through expression of PKM1 in Pkm2−/− mice
might be mitigated by both the down-regulation of total
Pkm transcripts and the reduction of PK enzymatic activ-
ity that we observed in Pkm2−/− tissues compared with
wild-type tissues.
Role of PKM2 in spontaneous HCC and systemic energy
homeostasis
Given the established role played by PKM2 in cancer
metabolism and that several reports implicate PKM2 spe-
cifically in HCC, it is striking that Pkm2−/−mice sponta-
neously develop large, multifocal liver tumors. It is
remarkable that the tumor formation that we observed
in Pkm2−/−mice occurs in the absence of a defined genet-
ic oncogenic driver event. Although both breast tumors
and leukemia have been shown to initiate and progress de-
spite loss of PKM2, these tumors arose in the context of
defined oncogenic events that are well-established drivers
of tumorigenesis. In contrast, in Pkm2−/− mice, HCC
tumor formationwas not driven by a defined cell-intrinsic
oncogenic driver event; rather, tumors appear to arise
through a stochastic process. Furthermore, because
the hepatocyte cells of origin for HCC do not express
PKM2, we suggest that HCC formation in Pkm2−/−
mice must arise through a non-cell-autonomous mecha-
nism. The finding that tumors from Pkm2+/− mice all
maintain the wild-type Pkm allele, as determined by
quantitative genomic PCR (data not shown), further sup-
ports this notion.
Nonetheless, cell-autonomous consequences of PKM2
loss are also potentially involved in HCC formation in
Pkm2−/− mice. Further investigation is needed to delin-
eate the precise mechanism by which non-cell-autono-
mous changes in PKM isoform selection promote liver
tumor formation.
Althoughmost cancermetabolism studies have focused
on cancer cell-intrinsic phenotypes, cell-extrinsic meta-
bolic changes, such as alterations in systemic metabo-
lism, are strongly associated with cancer (Pi-Sunyer
2009). Manifestations of systemic metabolic dysfunction
include insulin resistance, nonalcoholic fatty liver disease
(NAFLD), dyslipidemia, cardiovascular disease, systemic
inflammation, and metabolic syndrome, which encom-
passes many of these conditions (Kaur 2014). Although
these altered metabolic phenotypes are associated with
both increased incidence andmorbidity of a number of hu-
man cancers (Pi-Sunyer 2009; Esposito et al. 2012), the
link between metabolic disease and HCC is particularly
striking, with strong associations noted between HCC
and both type 2 diabetes andNAFLD (El-Serag et al. 2004).
In addition to promoting HCC development in aged
mice, germline loss of PKM2 increases susceptibility to
metabolic distress induced by either aging or a HFD. We
propose that the metabolic distress that develops in
Pkm2−/− mice leads to chronic liver injury and results in
both systemic and local liver inflammation, hepatocyte
proliferation, and, ultimately, HCC. Metabolite analysis
and RNA-seq data from liver samples taken prior to path-
ologically evident disease were indicative of a progressive
condition in which aberrations in metabolic and immune
response pathways preceded overt metabolic distress and
tumor formation in Pkm2−/− mice.
The molecular changes observed in prediseased livers
are likely the result of the non-cell-autonomous/systemic
and microenvironmental changes induced by germline
loss of PKM2 and consequent expression of PKM1 in other
cell types. While it is not immediately apparent which of
the many molecular changes are causative of the meta-
bolic distress and HCC that manifest with time, several
hepatocyte gene expression changes in Pkm2−/− livers
are consistent with changes observed in other HCC mod-
els. For example, up-regulation of Srebf1 has been shown
to result in increased hepatic triglyceride levels and is
one of the early and primary changes observed in liver-spe-
cific Pten knockoutmice, which also develop HCC (Horie
et al. 2004; Ueki et al. 2004; Knebel et al. 2012).
PKM2 loss promotes metabolic distress and HCC
GENES & DEVELOPMENT 1029
 Cold Spring Harbor Laboratory Press on May 9, 2016 - Published by genesdev.cshlp.orgDownloaded from 
Due to the widespread expression of PKM2 in adult tis-
sue, it is difficult to determine which tissues or cell types
are contributing to metabolic disease in Pkm2−/− mice.
Metabolic aberrations in PKM2-expressing tissues, in-
cluding white adipose tissue and pancreatic islet cells,
could be contributing to the systemic metabolic distress
that we observed in Pkm2−/− mice; however, it is likely
that PKM2 loss (and consequent PKM1 expression) across
tissues and cell types is involved. Future work on the sub-
ject is likely to lead to new insights into howPKM isoform
selection in different tissues contributes to systemic ener-
gy homeostasis.
The immune system has also been shown to play a key
role in both systemicmetabolic disease and the formation
of HCC. It is notable that all of the major phenotypes that
we uncovered in Pkm2−/−mice (late-onset hyperglycemia
and hyperinsulinemia, hepatic steatosis, inflammation,
and, ultimately, spontaneous HCC) are most pronounced
in aged male mice. Metabolic disease and HCC are also
more prevalent in men (El-Serag and Rudolph 2007). The
gender disparity observed in human HCC has been attrib-
uted in part to the inhibitory action of estrogen on inflam-
mation and, specifically, on the production of IL-6
(Naugler et al. 2007; Barros and Gustafsson 2011; Rahman
et al. 2013). Thus, an influence of inflammation and the
immune system may underlie the predisposition for met-
abolic distress and HCC in Pkm2−/− mice. The observed
increase of Il18mRNA and protein in Pkm2−/− livers fur-
ther supports this notion.
These findings provide new insights into the complex
roles played by PKM2 and glucose regulation in whole-
body and cancer cell metabolism. Pkm2−/− mice appear
to be a model that can be used to further investigate the
links between systemicmetabolism, the immune system,
and HCC progression. As a growing percentage of HCC
cases are associated with metabolic syndrome, type 2 dia-
betes, and NAFLD (Baffy et al. 2012; Rahman et al. 2013;
Byrne and Targher 2015), a better understanding of the
mechanistic link between systemic metabolic disease
and HCC formation is of crucial importance. An advan-
tage of thismousemodel is thatHCC arises in the context
of systemic metabolic distress, appears to be induced by
non-cell-autonomous events, and does not involve the
use of chemical tumor promoters. The future study of
Pkm2−/− mice will provide new avenues to further eluci-
date the distinct cell-intrinsic and cell-extrinsic roles of
PKM2 in both the normalmetabolic and inflammatory re-
sponses to aging and aberrant proliferation in the context
of cancer.
Materials and methods
Mice
Generation of the Pkm2fl/+ mouse strain has been described pre-
viously (Israelsen et al. 2013). Pkm2fl/+ and EIIA-Cremice (Lakso
et al. 1996) were crossed to obtain Pkm2+/− mice. All animals
were maintained on a mixed C57BL/6J × 129SvJ genetic back-
ground. The Massachusetts Institute of Technology (MIT) Insti-
tutional Animal Care and Use Committee approved all animal
studies and procedures. Genotyping primers used were 5′-TA
GGGCAGGACCAAAGGATTCCCT-3′ and 5′-CTGGCCCAG
AGCCACTCACTCTTG-3′.
RNA-seq data analysis
Sequencing was performed on an Illumina HiSeq 2000 instru-
ment to obtain paired-end 40-nucleotide reads. All reads that
passed quality metrics were mapped to the University of Califor-
nia at SantaCruzmm9mouse genome build (http://genome.ucsc.
edu) using RNA-seq by Expectation-Maximization (RSEM)
(Li and Dewey 2011; The ENCODE Project Consortium 2012).
Data normalization (MedianNorm) and differential analyses be-
tween experimental conditions were performed using EBSeq ver-
sion 1.4.0 (Leng et al. 2013). All RNA-seq analyses were
conducted in the R statistical programming language (http://
www.r-project.org). Heat maps were generated using the Heat-
plus package in R. GSEAs were carried out using the preranked
mode using log2 fold change values with default settings (Subra-
manian et al. 2005).
Isoform detection in external RNA-seq data sets
RNA-seqdata fromdifferentmouse tissuesproducedbyENCODE
(The ENCODE Project Consortium 2012) were analyzed for
PKM isoform-level read coverage using MISO (Katz et al. 2010).
Similarly, human tissue RNA-seq data sets from the Illumina
Body Map 2.0 project were analyzed for alternate isoform usage.
These stranded paired-end data sets were aligned to the mouse
(mm9) or human (hg19) genome builds using TopHat (Trapnell
et al. 2009).
Histology and IHC
Tissues were fixed in zinc formalin (Polysciences, Inc., 21516) at
room temperature and then transferred to 70% ethanol until par-
affin embedding. IHC was performed on 4-μm-thick sections us-
ing ABC VectaStain kit (Vector Laboratories) with antibodies to
PKM1 (1:500; Cell Signaling Technology, 7067), PKM2 (1:500,
Cell Signaling Technology, 4053), KI67 (1:100; Vector Laborato-
ries, VP-RM04), BrdU (1:100; Abcam, ab6326), HNF4α (1:200;
Sant Cruz Biotechnology, SC-6556), β-catenin (1:200; BD Biosci-
ences, 610154), glutamine synthetase (1:50; BD, 610517), NQO1
(1:500; Sigma,HPA007308), pERK (1:200; Cell Signaling Technol-
ogy, 4370s), p53 (1:100; Vector Laboratories, VP-RM04), and Iba1
(1:500; Wako Chemicals, 019-19741). The staining was visual-
ized with DAB (Vector Laboratories, SK-4100), and the slides
were counterstained with hematoxylin. For dual staining, DAB
and Vector Red (Vector Laboratories, SK-5100) or ImmPACT
VIP (Vector Laboratories, SK-4605) were used. Hematoxylin
and eosin (H&E) staining was performed on a Varistain Gemini
automated slide stainer (Thermo Shandon). The proliferation
analysis was performed using ImageJ to determine the number
of BrdU-positive cells per 4× field, five 4× fields were counted
per mouse, and at least five mice of each genotype were used
for the analysis. Human tissue arrays were purchased from US
Biomax, Inc., for normal human tissue (FDA808a1) and HCC
(HLiv-HCC060CD-02).
Immunoblotting
Tissue lysates were generated from flash-frozen groundwhole tis-
sue or tumors following lysis with ice-cold RIPA buffer supple-
mented with HALT phosphatase and protease inhibitors
(Thermo-Scientific, PI-78420 and 87786). Protein concentrations
of the cell lysates were quantified using the DC protein assay kit
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(Bio-Rad, 500-0112). Next, 15 μg of total protein was separated
on 4%–12% Bis-Tris gradient gels (Life Technologies) by SDS-
PAGE and then transferred to nitrocellulosemembranes. The fol-
lowing antibodies were used for immunoblotting: anti-β-tubulin
(1:10000; Sigma, T4026), anti-Hsp90 (1:10000; BD Biosciences,
610418), anti-γ-H2AX (1:1000; Cell Signaling Technology, 9718)
anti-PKM1 (1:5000; Cell Signaling Technology, 7067), and anti-
PKM2 (1:5000; Cell Signaling Technology, 4053).
PK activity
PK activity was measured as described previously (Christofk
et al. 2008b). Briefly, flash-frozen, ground tissue was lysed and
homogenized in hypotonic lysis buffer (20 mM HEPES, 5 mM
KCl, 1 mM MgCl2, 1 mM DTT) with HALT protease inhibitors.
Immediately prior to start, between 0.5 and 2 μg of protein was
mixed with 1× PK reaction buffer (100 mM KCl, 50 mM Tris-
HCl at pH 7.5, 5 mM MgCl2, 1 mM DTT) containing 0.5 mM
PEP (Sigma, P3637), 0.6 mM ADP (Sigma, A5285), 180 μM
NADH (Sigma, 8129), 16 μg of LDH (Sigma, 2500), and 100 μM
FBP (Sigma, F6803) where applicable. The final reaction volume
was 100 μL in 96-well plates, and all samples were tested in
duplicate.
Physiological and analytical measurements
Mice were fasted for 16 h prior to glucose measurement and plas-
ma collection. Glucose concentrations were measured using glu-
cose strips and a glucometer (Lifescan One Touch Ultra). Insulin
levels weremeasured using a mouse ultrasensitive insulin ELISA
kit (Crystal Chem, 90080). Serum triglycerides of fastedmice and
liver triglycerides from fed mice were measured using a triglycer-
ide assay kit (Cayman Chemical, 10010303). GTTwas performed
in 16-h-fasted mice using 1.5 g/kg glucose interperitoneal injec-
tion. Serum alanine aminotransferase measurements were per-
formed by IDEXX BioResearch Laboratory.
Cytokine analysis
Serum and tissue homogenate cytokines were quantified using
different Discovery assays (Eve Technologies Corp., assays
MD31, MYCTI-07-103, and MYCTI-06-101). The multiplex as-
say was performed at Eve Technologies by using the Bio-Plex
200 system (Bio-Rad Laboratories, Inc.).
BrdU incorporation
Mice were given one pulse of intraperitoneal injection with 30 μg
of BrdU per gram of mouse weight (Sigma, B5002) for 3 h.
Accession Numbers
All primary RNA-seq data are available on Gene Expression Om-
nibus under accession number GSE79535.
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